
Ipsen’s elafibranor shows promise in rare liver disease primary sclerosing cholangitis
Ipsen’s elafibranor has shown promise as a treatment for primary sclerosing cholangitis (PSC), a rare liver disease that currently has no approved treatment options. Results from the phase 2 ELMWOOD study, which has been comparing two doses of the drug …